Emcure Pharmaceuticals
Market cap ₹44,294 Cr
- P/E
- 40.51
- Day range
- ₹2,326.00 – ₹2,402.00
- 52-week range
- ₹1,312.30 – ₹2,429.90
- Volume
- 2.56 L
- Open
- ₹2,354.90
- Prev close
- ₹2,339.40
Latest results · Q2 FY27(consolidated)Revenue ₹2,820 Cr+24.3%Profit ₹325 Cr+29.3%Margin 11.5%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
EMCURE in NSE indices and F&O
Research profile
Composite 70 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.5%
- Graham no.
- ₹606.30
- vs Graham
- -74.0%
- ROE ÷ P/B
- 2.4%
- 12-1 mom.
- +27.6%
- Return / vol
- 1.93
- Magic Formula
- #244
- Piotroski
- 6/6
- FCF yield
- 0.9%
- PEG
- 1.38
Appears in 19 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Emcure PharmaceuticalsEMCURE | ₹44,294 Cr | 40.51 | 8.38 | 20.0% | 24.0% | 21.0% | 0.34 | +24.2% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 9h agoHeadlines about Emcure Pharmaceuticals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 39.8
- Price / Book
- 8.28
- ROE (FY26)
- 20.0%
- ROCE (latest year)
- 24%
- Dividend yield
- 0.15%
Moving averages (NSE)
- 20-day
- ₹2,059.57
- Price above
- 50-day
- ₹1,975.94
- Price above
- 200-day
- ₹1,764.2
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,668 | 1,771 | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 | 2,820 |
| Expenses | 1,374 | 1,460 | 1,479 | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 | 2,233 |
| Operating Profit | 294 | 311 | 336 | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 | 588 |
| OPM % | 18% | 18% | 19% | 19% | 18% | 19% | 20% | 21% | 21% | 19% | 21% | 21% |
| Other Income | 22 | 12 | 23 | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 | 3 |
| Interest | 61 | 65 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 | 36 |
| Depreciation | 84 | 91 | 94 | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 | 110 |
| Profit before tax | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 | 446 |
| Tax % | 30% | 27% | 26% | 26% | 32% | 24% | 26% | 26% | 26% | 29% | 26% | 27% |
| Net Profit | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 | 325 |
| EPS in Rs | ₹6.26 | ₹6.36 | ₹7.95 | ₹10.29 | ₹8.11 | ₹9.97 | ₹10.92 | ₹12.84 | ₹12.16 | ₹12.84 | ₹15.50 | ₹17.16 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-5 days since Mar 2021
-54 days since Mar 2021
-8 days since Mar 2021
-51 days since Mar 2021
+78 days since Mar 2021
Strengths, risks & growth
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally [1]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 8.29 times its book value
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +13%
- 3 Years
- +15%
- TTM
- +21%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +18%
- 3 Years
- +21%
- TTM
- +39%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- +70%
Return on Equity
- 10 Years
- —
- 5 Years
- +21%
- 3 Years
- +19%
- Last Year
- +20%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 77.87% | 77.87% | 77.83% | 77.82% | -0.01 pp |
| FII | 3.59% | 3.35% | 4.87% | 4.94% | +0.07 pp |
| DII | 6.10% | 6.10% | 8.46% | 8.49% | +0.03 pp |
| Public | 12.43% | 12.69% | 8.84% | 8.75% | -0.09 pp |
Filed with NSE for Sept 2026: promoters 77.82%, public 22.18%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 7.05% (+0.18 pp)- Promoters77.8%
- Foreign institutions4.9%
- Mutual funds7.0%
- Insurance1.2%
- Other domestic institutions0.3%
- Retail2.9%
- Others5.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Kotak Mid Cap Fund | 1.82% | 1.25% | +0.23 pp |
| Aditya Birla SL ELSS Tax Saver Fund | 0.57% | 1.89% | +0.09 pp |
| Nippon India Multi Cap Fund | 0.55% | 0.46% | -0.14 pp |
| SBI Flexicap Fund | 0.49% | 0.98% | +0.01 pp |
| Axis Small Cap Fund | 0.43% | 0.65% | +0.12 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 33.0%
- Downside volatility
- 28.6%
- Worst 5% of days
- 3.1%
- Average of that tail
- 3.8%
- Max drawdown (1Y)
- 12.7%
- Below its peak
- 1.1%
Against the market
- Beta vs Nifty 50
- 0.54
- Correlation
- 0.22
- Relative strength (3M)
- +20.7%
- ATR (14)
- 3.3%
Return
- Return 1M
- +28.2%
- Return 3M
- +24.6%
- Return 6M
- +38.5%
- Return 1Y
- +63.7%
- vs 200-day average
- +32.3%
Momentum
- RSI (14) · overbought
- 77.8
- MACD histogram
- 33.45
- Stochastic %K
- 87.9
- ADX (14)
- 45.7
- +DI / −DI
- 34.8 / 6.0
- Money flow index
- 87.5
Participation
- Delivery (20d avg)
- 53.4%
- vs its 60-day baseline
- -0.4 pts
- Volume vs 20-day
- -0.1σ
- Close vs day's VWAP
- -0.8%
- 52-week position
- 98 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
6 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹396 Cr
- FCF yield
- 0.9%
- Cash conversion
- 1.00
- Accruals ratio
- -0.000
- Net debt
- ₹1,620 Cr
- Net debt / equity
- 0.30
- EV / sales
- 4.49
- PEG
- 1.38
- Capex intensity
- 6.0%
- Revenue CAGR
- 21.1%
- Profit CAGR
- 39.5%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹3.60
Dividend - Rs 3.60 Per Share
4 Sept 2026ex-date - dividend₹3.00
Dividend - Rs 3 Per Share
14 Aug 2025ex-date
Company announcements
Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026
Transcript of Earnings Call - Q2 FY27 held on Tuesday, November 03, 2026 at 4:00 p.m. (IST)
Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026
Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026
Newspaper Publication of Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2026
Audio recording of Earnings Call - Q2 FY27
Presentation on Unaudited Financial Results for the quarter ended September 30, 2026
Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026
For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026.
Intimation for Earnings Call - Q2 FY27
Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial ....
Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026
Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited - Holding ....
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulatory Order(s)
Intimation of Closure of Trading Window
Filed with BSE (scrip 544210); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Sep 2026Slides
- Aug 2026TranscriptSlidesRecording
- Jun 2026Slides
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
Credit ratings
- Rating update · 31 Aug from care
- Rating update · 5 Dec 2025 from crisil
- Rating update · 17 Oct 2025 from crisil
- Rating update · 7 Oct 2025 from care
- Rating update · 6 Nov 2024 from crisil
- Rating update · 12 Aug 2024 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Emcure Pharmaceuticals: common questions
Answered from the figures on this page.